Correction-March2026 quarterly activity report & Appendix 4C
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report indicates that the open-label extension phase of the XanaMIA trial commenced, allowing participants to receive active treatment for an extended period. Financially, the company completed a significant capital raising and ended the quarter with a strong cash position, extending its runway beyond the expected release of trial results. The report also outlines ongoing commercial planning and regulatory engagement as the company prepares for potential marketing approvals for its lead compound, Xanamem.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- ACW XanaMIA Alzheimers open label trial commences
- ACW successfully completes $16.8m Placement and SPP
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
- Actinogen HY2025 financial report and Appendix 4D
Later from Actinogen Medical
- Actinogen receives positive scientific advice from EMA
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- ACW third positive XanaMIA trial data committee review
- Xanamem depression trial published in British J Psychiatry
- June 2026 Quarterly activity report & Appendix 4C
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical